Trajectory analysis reveals an uncommitted neuroblastic state in MYCN-driven neuroblastoma development
Collectively, the identification of this novel neuroblastoma-related cell subtype and its transcriptomic signature not only enhances our understanding of spontaneous regression mechanisms but also holds potential for therapeutic advancements in treating neuroblastomas.
Authors
- Teppei Shimamura (ORCID: https://orcid.org/0000-0003-2994-872X)
- Shoma Tsubota
- Yukie Kashima
- Yutaka Suzuki (ORCID: https://orcid.org/0000-0003-4852-1879)
- Janith A. Seneviratne (ORCID: https://orcid.org/0000-0003-0413-5829)
- Koji Tsuda (ORCID: https://orcid.org/0000-0002-4288-1606)
- Glenn M. Marshall (ORCID: https://orcid.org/0000-0002-2503-0762)
- Haruka Hirose (ORCID: https://orcid.org/0009-0007-3827-257X)
- Daniel R. Carter
- Kenji Kadomatsu
Institutions
- University of Technology Sydney (AU)
- Nagoya Institute of Technology (JP)
- UNSW Sydney (AU)
- Children's Cancer Institute Australia (AU)
- Sydney Children's Hospital (AU)
- Nagoya University (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1093/neuonc/noaf129
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Science and Technology Agency